Navigation Links
Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs

Researchers from MetroHealth Medical Center and Case Western Reserve University in Cleveland, OH found that treating expectant mothers// who have had previous spontaneous preterm births with 17 Alpha Hydroxyprogesterone caproate (17P) and reducing the incidence of another preterm birth would consequently reduce both short-term and lifetime medical costs in offspring by $2 billion per year. The results of their study are reported in the March issue of the American Journal of Obstetrics & Gynecology.

"In the United States, preterm birth is the leading cause of neonatal deaths and the leading cause of pediatric neuro-developmental disability, including cerebral palsy and mental retardation. It is also an important cause of chronic lung disease, visual impairment, and other chronic illness in children." That statement, from an editorial authored by Joanne Armstrong, MD, MPH, of Baylor College of Medicine in Houston, TX, and Senior Medical Director, Women's Health for Aetna, also appears in the March issue of the American Journal of Obstetrics & Gynecology. It reinforces why the results of the study are particularly significant.

Combining data from six studies of the costs of preterm births with estimates of the effectiveness of 17P in seven other studies, the investigators determined that initial neonatal hospital costs could be reduced by $3800 per woman treated and could lead to a reduction in lifetime medical costs of $15,900 per child. Senior investigator Jennifer Bailit MD, MPH, of the MetroHealth Medical Center states, "If the eligible population was universally treated with 17P, discounted lifetime medical costs of their offspring could be reduced by more than $2 billion annually. The potential societal savings from Medicaid coverage of 17P are substantial."

Dr. Armstrong continues in the editorial, "As more evidence accumulates about the effectiveness of 17P to prevent preterm birth, the current work of Bailit and colleagues p
'"/>




Page: 1 2

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
Other Medicine News:Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 2Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 3Health News:Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Children's Health Care? 4Health News:Fecal Blood Tests Effective at Spotting Colon Cancer 2Health News:Saint Vincent Health System of Erie, Pennsylvania Named One of AARP 2007 Best Employers for Workers Over 50 2Health News:Saint Vincent Health System of Erie, Pennsylvania Named One of AARP 2007 Best Employers for Workers Over 50 3Health News:Saint Vincent Health System of Erie, Pennsylvania Named One of AARP 2007 Best Employers for Workers Over 50 4Health News:Saint Vincent Health System of Erie, Pennsylvania Named One of AARP 2007 Best Employers for Workers Over 50 5Health News:Experts Agree. Ohio's Technology Investment Future Looks Bright 2Health News:Experts Agree. Ohio's Technology Investment Future Looks Bright 3Health News:PNY Technologies and Susan G. Komen for the Cure Partner to Raise Awareness of Breast Cancer 2Health News: Nosespray vaccine using aloe vera has exciting potential, researcher says 2
Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6L A Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 6309 1L A Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 6309 2L A Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 6309 3Par Pharmaceutical to Host Analyst Day on December 3rd 6307 1NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 1NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 2NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 3NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 4NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 5